# INDIBLADE (NCT05200988)

> Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC

No report yet. It can be ordered.

- Drugs tested: ipilimumab plus nivolumab
- Indication: muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05200988
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: The Netherlands Cancer Institute
- Conditions: Urothelial Carcinoma; Bladder Cancer
- Interventions: Ipilimumab + nivolumab
- Enrollment: 50
- Primary outcome: Efficacy defined as bladder-intact event-free survival (BI-EFS)

## Indexed commentary on INDIBLADE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- Podcasts: 7
- YouTube: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=indiblade-nct05200988

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05200988", "email": "<work email>"}; the inbox owner confirms by the emailed link.